Yanai Shlomo
SEC-identified person · CIK 1562645 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Philip Morris International Inc. pm | Director | filed 2021 - 2026 |
| Amneal Pharmaceuticals, Inc. AMRX | Director | filed 2019 - 2026 |
| W R Grace & CO GRA | Director | filed 2018 - 2021 |
| Cambrex Corp DBM | Director | filed 2012 - 2019 |
| Protein Design Labs INC/DE pdli | Director | filed 2018 - 2019 |
| Quinpario Acquisition Corp. 2 XELA | Director | filed 2015 - 2017 |
| Sagent Pharmaceuticals, Inc. [NONE] | Director | filed 2015 - 2016 |
| Perrigo Co plc PRGO | Director | filed 2015 - 2016 |
| Protalix Biotherapeutics, Inc. PLX | Director | filed 2014 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.